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Background: Recent genetic association studies have investigated the possible genetic role of the dopaminergic 
system in migraine. Catechol-O-methyltransferase (COMT) is an enzyme that plays a crucial role in the metabolism 
of dopamine and its genetic polymorphism is associated with three- to fourfold variation of enzymatic activity.
Objectives: The objective of this study was to elucidate the role of the COMT polymorphism in the genetic 
susceptibility to migraine and its phenotypic expression in patients with migraine without aura (MWOA).
Methods: Ninety-seven patients with MWOA and 94 healthy volunteers were included in the study. After 
amplifying COMT genes by the polymerase chain reaction, we assessed their genotype frequencies and allele 
distributions by based on restriction fragment length polymorphisms. We classified all MWOA patients into two 
groups according to their COMT genotype: with the L allele (N = 43), and without this allele (N = 54).
Results: The genotype frequency and allele distribution of the COMT polymorphism did not differ between 
MWOA patients and the control group. During migraine attacks, MWOA patients with the L allele showed a higher 
pain intensity of headache (P = 0.001) and a higher incidence of the accompanying nausea/vomiting (94% vs 75%; 
P = 0.026) compared with MWOA patients without the L allele.
Conclusions: A l t h o u g h  t h e  C O M T  p o l y m o r p h i s m  d o e s  n o t  a p p e a r  t o  b e  i n v o l v e d  in  predisposition  to  the 
development of MWOA, this genetic factor could be involved in the phenotypic expression of MWOA.
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INTRODUCTION
Many investigators have reported that dopaminergic 
neurotransmission is altered in migraineurs.
1–4 The fre-
quency and severity of attacks in migraineurs decreases 
after the development of Parkinson’s disease, and serum 
levels of dopamine increase in patients with migraine 
without aura (MWOA).
5,6  Clinical trials involving treat-
ment with dopamine receptor antagonists for migraine 
provide strong evidence for the involvement of dopa-
mine.
7,8 The accompanying symptoms during the migraine 
attack (nausea, vomiting, dizziness, and orthostatic faint-
ness) may be related to dopaminergic activation.
9–11
Migraine shows strong familial aggregation and pre-
sumably has a genetic basis, but the type and number of 
genes involved are currently unclear.
12–14 Recent genetic 
association studies have investigated the possible genetic 
role of the dopaminergic system in migraine. Catechol- 
O-methyltransferase (COMT) is an enzyme that inactivates 
catecholamines or catechol-containing drugs. The gene 
encoding for COMT has been mapped to chromosome Park JW, et al. Catechol-O-methyltransferase Polymorphism in Migraine without Aura
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22q11.
15 Several studies indicate that the genetic poly-
morphism due to a G→A substitution at codon 158 of 
the COMT gene, leading to a valine-to-methionine sub-
stitution, results in differences in COMT activity: a 
valine at codon 158 results in a heat-stable, high-activity 
COMT variant, whereas a methionine at this position 
results in heat-labile, low-activity variants.
16,17  The 
potential role of this functional polymorphism of COMT 
in Parkinson’s disease and other neuropsychiatric dis-
orders, including schizophrenia and bipolar affective 
disorders, has already been investigated.
17–20 However, 
few studies have examined the association between 
COMT polymorphisms and migraine.
21 Moreover, no 
study has investigated the phenotypic expression of 
dopamine-related accompanying symptoms.
We therefore investigated the possible role of COMT 
enzyme polymorphism in the genetic susceptibility to 
migraine and its phenotypic expression.
SUBJECTS AND METHODS
Subjects
All subjects included in this study were identified 
from a larger pool of subjects involved in an ongoing 
prospective study of the genetic contribution to headache 
at the headache clinic of the Catholic university of 
Korea. Ninety-seven patients with MWOA consecutively 
recruited from the headache clinic, and 94 healthy 
normal subjects without MWOA agreed to participate in 
this study. None of the participants were from the same 
family. The migraine patients and healthy control group 
were closely age matched. Given the known effects of 
gender on this gene system, only women were included 
in this study. This study was approved by the institu-
tional ethnical committee of our institute, and written 
informed consent was obtained from all participating 
subjects.
All participants were interviewed clinically and ex-
amined physically and neurologically by an experienced 
neurologist. Psychiatric interviews were performed by a 
psychiatrist, and patients with personality or major psy-
chiatric disorders were excluded according to DSM-IV 
criteria. During the interview, detailed data were ob-
tained regarding clinical symptoms and headache 
variables using a structured questionnaire. The diagnosis 
of MWOA was made based on the operational diagnostic 
criteria of the International Headache Society (ICHD-II 
[International Classification of Headache Disorders]).
22 
We did not include patients suffering migraine with 
aura, because there were too few of them in the pool of 
subjects from which they were selected.
Determination of the COMT genotype
Blood samples were collected into heparinized tubes 
and stored at -80℃ before isolation of DNA. Genomic 
DNA was isolated and amplified by the polymerase 
chain reaction (PCR) using the specific oligonucleotide 
primers 5´-CTC ATC ACC ATC GAG ATCAA-3´ and 
5´-GAT GAC CCT GGT GAT GTGG-3´. PCR reaction 
mixtures contained 50 ng of genomic DNA, 50 pmol of 
each primer, 10 mM Tris-HCL, 50 mM KCl, 50 mM 
MgCl2, 0.01% Tween 20, each of dATP, dCTP, dGTP, 
and dTTP at 0.2 and 2.5 units of Taq polymerase in a 
total volume of 100 µL. The following cycling con-
ditions were used: (1) an initial denaturation at 95℃ for 
3 min; (2) three cycles of denaturation at 94℃ for 30 s, 
touch-down annealing at 65℃ for 1 min, and synthesis 
at 72℃ for 1 min; (3) 34 cycles of denaturation at 94℃ 
for 30 s, annealing at 63℃ for 1 min, and synthesis at 
72℃ for 1 min; and (4) a final extension at 72℃ for 
10 min. PCR was conducted in a thermal cycler 
(BioRad, Richmond, California).
The resulting PCR products were subjected to 
restriction digestion for 3 h at 37℃ using 5 U NlaIII 
(New England BioLabs, Beverly, Massachusetts). 
The digested products were separated at 150 V for 
2 h on a 4% NuSieve 3:1 agarose gel (FMC Bio-
Products, Rockland, Maine) containing 0.5 g/mL ethidium 
bromide. The gel was visualized under UV light using 
a gel electrophoresis visualization system (Vilber 
Lourmat, Marne La Vallée, France). The COMT-Met/ 
Met genotype (L/L) was represented by 54-, 67-, and 
71-bp fragments, COMT-Met/Val (L/H) by 54-, 71-, and 
85-bp fragments, and COMT-Val/Val (H/H) by 54-, 67-, 
71-, and 85-bp fragments. The 18-bp fragment was Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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Table 1. Distributions of genotypes and allele frequencies of the catechol-O-methyltransferase (COMT) polymorphism in patients 
with migraine without aura (MWOA) and in controls
Genotype distribution (%) Allele frequency (%)
Subject group N L/L (Met/Met) L/H (Met/Val) H/H (Val/Val) N L (Met) H (Val)
MWOA 97 6 (6%) 37 (38%) 54 (56%) 194 49 (25%) 145 (75%)
Control 94 9 (10%) 38 (40%) 47 (50%) 188 56 (30%) 132 (70%)
Genotype distribution: 
 = 1.05 (two degrees of freedom), P = 0.059
Allele frequency: 
= 0.983 (one degree of freedom), P > 0.05
difficult to visualize because of both its small size and 
its comigration with the similarly sized primer residue; 
however, detection of this fragment was not critical to 
determining the genotypes. Genotyping was based upon 
independent scoring of the results by two reviewers who 
were unaware of the case/control status.
Associations of migraine phenotypes with COMT 
genotypes 
We classified all patients with MWOA into two 
groups according to their COMT genotype: those with 
the L allele (N = 44, L/L and L/H genotype) and those 
without this allele (N = 53, H/H genotype). The physical 
variables of the patients’ headaches were evaluated 
according to the pain index of headache intensity, as 
measured on a visual analog scale (scale anchored with 
0 and 10, where 0 means no pain at all and 10 means 
pain as bad as it can be), the headache frequency (per 
month), and the duration of each headache attack (hours) 
during the previous 6 months. Clinical manifestations 
associated with MWOA (location, quality, aggravation 
by activity, nausea/vomiting, phonophobia/photophobia, 
and dizziness) were assessed during this evaluation. 
Photophobia and phonophobia (0, at least one present; 1, 
both present) as well as nausea and vomiting (0, not 
present; 1, at least one present) were combined into a 
single index variable for later analysis.
Data analysis
Comparisons of genotype distribution and allele 
frequency were performed on raw frequencies using a 
chi-squared test. A chi-squared analysis of the Hardy- 
Weinberg equilibrium for the genotypes was conducted 
to determine whether the allele frequencies were stable 
within the patients and controls. Comparisons of clinical 
symptoms and physical variables of migraine according 
to the COMT allele were performed using the t-test for 
parametric variables and the chi-squared test for non-
parametric variables. SPSS statistical software (version 
10.0; SPSS, Chicago, Illinois, USA) was used for all the 
analyses, with a probability value of P < 0.05 considered 
significant.
RESULTS
The genotype distributions in patients with MWOA 
and controls did not deviate from those expected based 
on the Hardy-Weinberg equilibrium. Table 1 indicates 
that the COMT genotype distribution and allele fre-
quencies did not differ significantly between MWOA 
patients and controls.
The pain intensity of headache was significantly 
higher in patients with the L allele than in those without 
this allele. Variables including the headache frequency 
and duration of headache attack did not differ signifi-
cantly between the two groups (Table 2). Nausea or 
vomiting accompanying migraine attacks was more 
frequent in patients with L allele than in those without 
this allele (94% vs 75%, P = 0.026). Although the 
tendency to experience dizziness during a migraine 
attack was higher in patients with the L allele than in 
those without this allele (63% vs 47%), the difference 
was not statistically significant (Table 2).Park JW, et al. Catechol-O-methyltransferase Polymorphism in Migraine without Aura
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Table 2. Clinical symptoms of patients with MWOA according to their COMT polymorphism
Characteristic Total MWOA 
with L allele 
MWOA 
without L allele P 
Number of subjects 97 43 54
Headache frequency (per month)  5.42±3.03  5.42±2.76  5.43±3.27 > 0.05
Duration of each attack (hours) 14.32±8.81 15.20±8.43 13.58±9.17 > 0.05
Average intensity of pain (VAS)  8.18±1.70  8.96±1.11  7.52±1.84 0.001
Incidence of symptoms
Unilateral headache 61% 64% 60% > 0.05
Throbbing pain 82% 85% 79% > 0.05
Nausea/vomiting 84% 94% 75% 0.03
Phonophobia/photophobia 44% 46% 43% > 0.05
Dizziness 54% 63% 47% > 0.05
VAS; visual analog scale
Table 3. Summary of association studies investigating dopamine-related genes in migraine
Gene Migraine type Sample size  Significance Source
DRD2 MWA 52 P < 0.005 Peroutka et al.
24
MWOA 77 NS
MWOA 22 P = 0.004 Del Zompo et al.
25
MWA/MWOA 102 NS Dichgans et al.
26
MWA/MWOA 177 NS Lea et al.
27
DRD1 MWA/MWOA 262 NS Shepherd et al.
28
DRD3 MWA/MWOA 252 NS Shepherd et al.
28
MWOA 50 NS Del Zompo et al.
25
DRD4 MWOA 50 NS Del Zompo et al.
25
MWOA 202 P < 0.002 Mochi et al.
29
MWA 186 NS
DRD5 MWA/MWOA 273 NS Shepherd et al.
28
DβH MWA/MWOA 284 P = 0.006 Lea et al.
27
MWA/MWOA 284 NS
MWA/MWOA 388 NS Mochi et al.
29
DAT MWA/MWOA 388 NS Mochi et al.
29
MAO-A MWA/MWOA 119 NS Marziniak et al.
31
MWOA 80 P = 0.042 Filic et al.
30
MAO-B MWOA 80 NS
COMT MWA/MWOA 62 P = 0.013 Ermin Erdal et al.
21
MWOA 97 NS Present study
DRD; dopamine receptor gene, DβH; dopamine beta hydroxylase gene, DAT; dopamine transporter gene, MAO; monoamine 
oxidase gene, MWA; migraine with aura
NS;  P > 0.05
DISCUSSION
Interest in the contribution of dopaminergic pathways 
to migraine biogenesis stems from reports of the in-
duction of migraine by dopaminergic agonist at doses 
that do not appear to affect nonmigraineurs.
10,23  Migraine 
association studies investigating dopamine-related candi-
date genes have produced some interesting but as yet 
inconclusive results (Table 3).
21,24–31  A recent analysis of 
the association between COMT polymorphism and 
migraine in a Caucasian population revealed that the Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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frequency of the L/L genotype was higher in migraine 
patients.
21 However, in the present study we found no 
differences in the genotype distribution and allele 
frequency of the COMT polymorphism between patients 
with MWOA and controls. The interactions of the 
dopaminergic system are complex, and the control of 
dopamine activity may be determined by various 
enzymes involved in dopamine metabolism. Therefore, 
this possibility could be considered in addition to ethnic 
differences.
32–36
In this study, the pain intensity of headache was 
higher and the associated nausea and/or vomiting was 
more common in patients with the L allele. The higher 
dopaminergic activity could presumably result from the 
COMT activity being lower in individuals with the L 
allele than in those without this allele. With regard to 
migraine headache, basal ganglia and dopaminergic 
neurotransmission are well known to be involved in the 
regulation of nociception.
37  Administration of L-dopa 
facilitates the perception of pain in rats, and L-dopa 
agonists can induce pain in Parkinson’s patients.
38,39 
Dopamine antagonists are commonly and successfully 
used to reduce pain intensity of headache in acute 
migraine, which is additional to their antiemetic 
effect.
7,8,40,41 Symptoms accompanying migraine, such as 
nausea, vomiting, and dizziness, may be mediated by 
dopaminergic activation.
9–11 Different expression of the 
D2 family receptor in the brainstem has been frequently 
reported in patients with migraine, which may be due to 
these receptors regulating visceral function, including 
gastrointestinal motility and blood pressure.
42,43 D 2, D3, 
and D4 receptors have been detected in intermediate and 
medial subnuclei among the nucleus of the solitary tract 
and in the dorsal motor nucleus of the vagus. D3 
receptors are also found in the area postrema. Peripheral 
D2  receptors are located presynaptically on sympathetic 
nerves and ganglia, and may be the mechanism by 
which dopaminergic stimulation induces dizziness or 
orthostatic hypotension.
44 Del Zompo, et al. studied 
genetic aspects of dopamine receptor polymorphism in 
migraine patients, and considered that “dopaminergic 
migraineurs” - selected based on the presence of both 
nausea and vomiting during the pain phase of migraine 
- could be differentiated from “nondopaminergic 
migraineurs”.
25 In their study, although no association 
was detected between dopamine receptor polymorphism 
and migraine in the overall groups, the allelic dis-
tribution differed significantly according to the existence 
of dopaminergic symptoms.
25 Considering those studies, 
our results suggest that genetic factors of dopaminergic 
system are involved in the associated clinical mani-
festation of MWOA. The COMT polymorphism may be 
of potential pharmacological importance regarding in-
dividual differences in the metabolism of dopaminergic 
drugs in patients with MWOA. Moreover, antidopami-
nergic drugs may be useful as an antimigraine treatment 
in patients who are refractory to primary treatment and 
have prominent accompanying dopaminergic symptoms.
In conclusion, our results do not confirm an asso-
ciation of MWOA with the COMT gene, but they do 
suggest that allelic variation in COMT is involved in the 
phenotypic expression of migraine in some individuals.
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